The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

NCT06044467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

DRUG: Anti-human CCL24 monoclonal antibody (CM-101) - Part One
DRUG: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
DRUG: Placebo - Study Part One
DRUG: Placebo - Study Part Two

Sponsor

ChemomAb Ltd.